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within the four questions. Respondents were willing to sacrifice median 5 and 
8 years of their remaining lifespan until the age of 80 years for avoiding two 
migraines per month and per week, respectively. Mean utilities for two migraines 
each month were U20m= 0.84 (SD 0.26) and U80m= 0.89 (SD 0.14), and for each 
week were U20w= 0.79 (SD 0.27) and U80w= 0.83 (SD 0.17), respectively. Self-reported 
migraneurs elicited higher mean utilities compared to non-migraneurs for all 
migraine health states but this difference was statistically significant only for 
U80m (p= 0.039). Also, males attached lower mean utilities for all health states 
than females but this was significant only for U80m (p= 0.018). Besides, older 
respondents valued higher mean utilities for U20m compared to the younger ones 
(p= 0.040). ConClusions: Our findings provide the first time trade-off utilities 
on migraine associated HRQOL impairment. Disutility caused by migraine ranged 
between 0.1 and 0.2 depending on attack frequency.
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objeCtives: This research reviews the research literature reporting humanistic 
outcomes related to multiple sclerosis (MS) in Latin America. Methods: We con-
ducted a systematic search of Medline, Embase, LILACS and Scielo from inception 
through 2013 for articles reporting original research on quality of life (QoL), utility 
scores for states of MS, patient preference, mental health, social and emotional 
wellbeing in people with MS in Latin America. Adherence and related issues were 
not included. Outcomes were categorized into: mental domain (cognitive function; 
mental health), physical domain (mobility/independence; fatigue; restless legs syn-
drome), employment, QoL, caregiver burden, and patient preference. Results: A 
total of 38 studies were selected for analysis. Among them, 23 addressed issues in 
the mental domain (9 cognitive functions and 14 mental health), 41 in the physical 
domain (24 mobility/physical function, 15 fatigue and 2 restless legs syndrome). 
One addressed impact of MS on employment, 16 QoL, 2 caregiver burden and 1 
patient preference. Researchers used 56 different instruments to collect their data 
from 2286 patients. Compared with controls, MS patients had significantly (P< 0.05) 
lower levels of functioning, cognition and increased presence of mental illness. All 
of these factors were significantly associated with decreased QoL in patients (odds 
ratios ranged from 4.2-10.1; P< 0.05). Similarly, fatigue and restless legs syndrome 
correlated significantly with anxiety, depression and level of mobility/functioning as 
well as QoL. ConClusions: As in other parts of the world, MS exerts a substantial 
negative impact on the lives of people with MS in Latin America. It lowers their QoL 
and interferes with their ability to move about, care for themselves and work. Their 
social life is also negatively affected. The amount of literature on this subject is 
quite limited. More research in Latin America is needed to understand humanistic 
outcomes in these patients and management of their MS.
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objeCtives: The aims of this study were to quantify the burden of insomnia and 
to quantify the association between side effects of insomnia medications and 
health outcomes. Methods: Data from the 2013 US (N= 75,000) and 5EU (N= 62,000) 
National Health and Wellness Survey (NHWS) were used. The NHWS is a patient-
reported survey administered to a demographically representative sample of adults 
(with respect to age, sex, race/ethnicity, and region). Those who met DSM-V criteria 
for insomnia and, separately, those treated with insomnia were compared with their 
respective propensity score-matched control groups on health status (SF-36v2), work 
productivity (WPAI-GH), and health care resource use using ANOVA tests. Among 
those with treated insomnia, those with and without side effects were compared on 
health outcomes using general linear models controlling for demographics, health 
history, and comorbidities. Results: Compared with their respective matched con-
trol groups, patients with insomnia (n= 4147) and treated insomnia (n= 2860) in the 
5EU reported significantly worse mean health utilities (0.60 vs. 0.74; 0.60 vs. 0.74, 
respectively), greater overall work impairment (38.74% vs. 14.86%; 39.50% vs. 15.66%), 
and more annual physician visits (9.10 vs. 4.08; 9.58 vs. 4.11). Similar findings were 
observed in the US cohort. Among those treated for insomnia, 13.56% and 24.55% 
in the US and 5EU, respectively, were non-adherent due to side effects. In the US, 
this behavior was associated with significantly worse health utilities (0.60 vs. 0.64) 
and greater overall work impairment (37.71% vs. 29.08%), among other variables 
(all p< .05). These relationships were not significant in the 5EU. ConClusions: A 
significant humanistic and economic burden of insomnia was observed in both the 
US and 5EU, and the burden remains even after treatment. Non-adherence due to 
side effects was common and, in the case of the US, associated with significantly 
poorer health outcomes.
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objeCtives: To evaluate the effect of prolonged-release (PR) fampridine 10 mg 
tablet on generic quality of life (QoL) as measured by the EQ-5D in patients with 
multiple sclerosis (MS) with walking impairment. Methods: The study popula-
tion included 132 patients who enrolled in a 24-week randomized, double-blind, 
and placebo-controlled phase 2 trial (NCT01597297) of PR-fampridine 10 mg tab-
lets or placebo twice daily in multiple sites in Europe and Canada. Patients were 
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objeCtives: To compare 6-month persistence rates among patients receiving the 
multiple sclerosis (MS) disease-modifying therapies (DMTs) fingolimod or interferon/
glatiramer acetate (IFN/GA) (index DMT), using open- and closed-source data that 
reflect unrestricted or continuous health care coverage, respectively. Methods: 
Retrospective analyses used administrative claims and mail-order pharmacy data-
bases (IMS PharMetrics Plus™ [closed]) and LRx™ [open], respectively). All patients 
were ≥ 18 years old and naive to fingolimod and index DMT, had ≥ 1 prescription for 
index DMT between 01-Oct-2010 and 31-Mar-2013 and had not received multiple 
DMTs at index date. An additional PharMetrics cohort was selected using more 
stringent criteria (continuous enrolment pre-/post-index; MS diagnosis code). 
LRx prescriptions were collected from pharmacies supplying ≥ 1 claim for index 
DMT between the index date and the last month of follow-up. Persistence was 
defined as time from initiating index DMT until discontinuation (gap ≥ 60 days), 
receipt of another DMT or end of the 6-month follow-up period. Risk of and time 
to discontinuation were assessed by a Cox proportional hazards model (control-
ling for age, gender and region) and Kaplan-Meier analysis, respectively. Results: 
Using identical criteria, 22,467 PharMetrics patients (fingolimod: n= 1968; IFN/GA: 
n= 20,499) and 49,803 LRx patients (8325 and 41,478, respectively) were selected. 
Proportions of patients discontinuing index DMT were significantly lower for fin-
golimod vs IFN/GA (PharMetrics: 23.1% vs 27.2%; LRx: 26.9% vs 33.4%; p< 0.0001). Risk 
of discontinuation was higher for IFN/GA vs fingolimod (PharMetrics: hazard ratio, 
HR= 1.18; 95%CI: 1.07–1.30, p= 0.0008; LRx: HR= 1.23; 95%CI: 1.17–1.29, p< 0.0001). Time 
to discontinuation was significantly longer for fingolimod vs IFN/GA (PharMetrics: 
p= 0.0005; LRx: p< 0.0001). With more stringent criteria used in PharMetrics, risk 
of discontinuation of IFN/GA vs fingolimod increased (HR= 1.47; 95%CI: 1.24–1.74, 
p< 0.0001). ConClusions: Both data sources provided similar results, supporting 
use of open-source LRx data, which allows access to up-to-date information that 
can improve sample size and statistical power.
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objeCtives: Traditional valuation methods are insensitive to small improvements 
in process and outcome of care. Best-Worst scaling (BWS) was proposed as a sensi-
tive and efficient method to determine the relative value of different treatments 
for the same disease, which would be desirable to estimate cost-effectiveness. The 
study objective was to compare the ability of BWS to differentiate between dif-
ferent treatment alternatives to that of Time Trade Off (TTO) and Visual Analogue 
Scales (VAS). Methods: An online survey was conducted to estimate individual 
values for six different treatments reflecting the real-life options in the treatment 
of Parkinson’s Disease with BWS2, BWS3, TTO and VAS (n= 592). Pearson correla-
tion coefficient was used to examine the strength of linear dependence between 
estimated utility scores. Results: Twenty-seven percent of respondents was not 
willing to trade life years in TTO. Only two percent of the respondent does not 
differentiate between the value of health states with VAS. When non-traders were 
excluded from the analysis, the best case scenario was valued significantly higher 
than the worst case scenario with all methods. Rank reversals among intermedi-
ate alternatives were common. The correlation between utility scores was very 
strong (VAS-BWS2 1,0; VAS-BWS3 0.98; TTO-BWS2 0.99; TTO-BWS3 0.98, BWS2-
BWS3 0.96; P< 0.000, n= 434). ConClusions: The results demonstrate that BWS, 
TTO and VAS can be used to elicit incremental utility gain of small improvements 
in care. However, all methods have limitations. VAS does not result in utilities 
and some respondents do not trade with TTO. While the use of BWS is attractive 
because of its ability to estimate utilities for many different treatment alterna-
tives, its applicability in CEA is limited because BWS utilities are not anchored on 
a 0-1 utility scale. We propose to use TTO to estimate utility for extreme health 
states, and to use BWS to value intermediate health states which differ on process 
characteristics.
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objeCtives: To evaluate health-related quality of life (HRQOL) in migraine based 
on attack frequency by time trade-off method (TTO) in a mixed population sam-
ple consisting of migraneurs and non-migraneurs. Methods: A cross-sectional 
questionnaire survey was designed to measure HRQOL in migraine without aura 
by TTO. A convenience sample was recruited from university students and staff 
regardless of having ever experienced migraine or not. Participants were asked to 
elicit two hypothetical health states characterised by different migraine frequency 
(‘m’: two migraines lasting 4 hours each month and ‘w’: each week) within two 
hypothetical lifetime frames (20 years left to live/lives until the age of 80 years). 
Utilities were calculated for the four tasks (U20m, U80m, U20w, U20w) and com-
pared between subgroups. Results: Altogether 180 respondents were included 
in the analysis. Mean age was 25.6 years (SD 6.4), 71% were female and 61% were 
self-reported migraneurs. Proportion of non-traders varied between 14% and 43% 
